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ABSTRACT
Background: Survival of colorectal cancer in Indonesia is thought to be shorter due to to several factors, 
among these: ethnic, nutritional, and the low affordability factors. Aim of this study to assess and evaluate survival 
in advanced colorectal cancer when given the best drugs available as recommended by international guidelines.
Method: A historical cohort study was done in patients with advanced colon or rectal cancer between 2008 
and 2010 at Medistra Hospital. Cases were retrieved from medical record data. Subjects were included if they 
were diagnosed or had a relapse of their disease during the study period and were followed until they died or lost 
to follow-up. Staging procedure was done using the tumor node metastasis (TNM) system. All patients received 
the combination of 5- uorouracil (5-FU)/leucovorin (LV), oxaliplatin for 6 cycles (FOLFOX4) as the standard 
 rst-line regimen for metastatic colorectal cancer (mCRC) in Indonesia. Oral capecitabine and targeted therapy 
such as bevacizumab and cetuximab might were also given, whenever indicated.
Results: Nineteen patients (48.7%) died during the study period, while the rest were alive or lost to follow-up. 
The median overall survival of patients was 18 months (95% CI = 6.98 – 29.02 months). The longest survival was 
76 months (the patient is still alive when this manuscript was being prepared). Patients with colon cancer tended 
to live longer than rectal cancer, i.e. 21 vs. 15 months; log-rank p = 0.147. There was no signi cant difference 
of survival between patients with stage IV disease and relapse cases, i.e. 18 vs. 12 months, log-rank p = 0.807. 
Conclusion: With proper treatment and access to cytostatics and biologicals, advanced colorectal cancer 
among Indonesian patients have the same survival rates as patients in more developed countries as reported 
in the literature. 
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ABSTRAK
Latar belakang: Kesintasan kanker kolorektal di Indonesia agaknya lebih singkat karena beberapa faktor, 
di antaranya adalah suku, gizi dan kemampuan yang rendah. Tujuan penelitian ini adalah untuk mengkaji dan 
menilai kesintasan kanker kolorektal tahap lanjut ketika pasien diberikan obat-obat terbaik yang tersedia di 
pasaran sebagaimana disarankan oleh pedoman internasional. 
Metode: Penelitian kohort retrospektif dilakukan pada pasien dengan kanker kolon atau kanker rektum tahap 
lanjut antara tahun 2008 dan 2010 di Rumah Sakit Medistra. Kasus didapatkan berdasarkan data rekam medik. 
Subyek penelitian diikutsertakan bila pasien didiagnosis atau menderita relaps penyakit selama periode penelitian 
dan diikuti hingga mereka meninggal atau hilang untuk ditindaklanjuti. Prosedur penetapan stadium kanker 
dilakukan dengan menggunakan sistem tumor node metastasis (TNM). Semua pasien mendapatkan kombinasi 
5  uorourasil (5-FU)/leukovorin (LV), oksaliplatin selama 6 siklus (FOLFOX4) sebagai regimen lini pertama 
standar untuk metastasis kanker kolorektal di Indonesia. Kapesitabin oral dan terapi target seperti bevakizumab 
dan setuksimab juga diberikan, bilamana diperlukan. 
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Hasil: Sembilan belas pasien (48,7%) meninggal dunia selama periode penelitian, selebihnya masih hidup 
atau tidak dapat ditindaklanjuti. Nilai median dari kesintasan hidup pasien secara keseluruhan adalah 18 
bulan (95% CI = 6,98 – 29,02 bulan). Kesintasan hidup terlama adalah 76 bulan (pasien masih hidup ketika 
manuskrip ini disiapkan). Pasien dengan kanker kolon cenderung hidup lebih lama daripada kanker rektum, 
yakni 21 bulan dibandingkan 15 bulan; nilai p log-rank = 0,147). Tidak ada perbedaan yang bermakna dalam 
hal kesintasan antara pasien dengan penyakit stadium IV dan kasus-kasus relaps, yakni 18 bulan dibandingkan 
12 bulan dengan nilai p log-rank = 0,807. 
Simpulan: Dengan pengobatan yang tepat dan akses menuju obat-obat sitostatik dan biologik, kanker 
kolorektal tahap lanjut pada pasien-pasien di Indonesia mempunyai tingkat kesintasan hidup yang sama dengan 
pasien-pasien di negara yang lebih maju sebagaimana yang dilaporkan dalam kepustakaan.
 
Kata kunci: kanker kolorektal tahap lanjut, kemoterapi, kesintasan 
INTRODUCTION
Colorectal cancer is the fourth most common 
cancer in Indonesia with an estimated age-standardized 
incidence of 17.2 per 100,000 populations for both 
sexes.1 About 20% of patients present with distant 
metastasis, conferring a 11.9%, 5-year relative survival 
in some reports.2,3 In another report cancer registry in 
Indonesia is still being developed, but data from a private 
hospital in Jakarta (unpublished) revealed that 34% 
of colorectal patients presented at a metastatic stage. 
In many instances, patients with metastatic colorectal 
cancer (mCRC) in Indonesia often do not receive 
adequate treatment because of the prohibitive cost of 
treatment and the perception – from doctors and patients 
alike - that the effort is futile and that the patient will not 
live longer despite the high cost treatment.
For many decades, 5- uorouracil (5-FU) has been 
the mainstay of treatment for mCRC with a very 
short survival. The addition of oxaliplatin to 5-FU has 
improved overall survival and response rate compared 
with 5-FU alone.4,5 Currently, the combination of 
multiple agents with 5-FU, leucovorin (LV) and 
oxaloplatin (FOLFOX) has been the standard regimen 
for  rst line chemotherapy for metastatic CRC.6 This 
regimen has prolonged median survival to about 20 
months in patients with mCRC.7,8 In recent years, 
FOLFOX plus bevazicumab as a second-line therapy in 
patients who previously has been treated with 5-FU/LV 
and irinotecan (FOLFIRI) showed a median survival 
of 10.7 months,9 thus ushering the era of “biological” 
as part of the systemic treatment armamentarium for 
colorectal cancer, notably for stage IV.
An important factor that has been mentioned in the 
literature is the different outcomes of treatment, with 
the tenet “A drug which work for one patient may 
not work in another patient with the same cancer” in 
which not just ethnicity or race but socioeconomic 
status is a factor, an observation reported even in 
the United States.10 The analogy is not missed in the 
Indonesian population where, with the wide spectrum 
of affordability and access to the best medical care, 
different outcomes are to be expected. Although the 
benefit of combination chemotherapies has been 
established elsewhere, less is known in developing 
countries, including Indonesia. No study has been 
conducted in Indonesia addressing the ef cacy of multi 
cytotoxic agents on the patient’s survival for those who 
can afford the best treatment. The aim of this study is 
to evaluate the survival of metastatic colorectal cancer 
in the patients, and a good source of study would be 
a private hospital.
METHOD
This is a historical cohort study of patients with 
advanced colon or rectal cancer between 2008 and 2010 
in Medistra Hospital. Cases were retrieved from medical 
record data. Subjects were included if they was diagnosed 
or had a relapse disease during the study period and were 
followed until they died or the last follow-up. Patients 
with no record of any kind of treatment or other primary 
cancer were excluded from the analysis.
Diagnosis of colon or rectal cancer was established 
histopathologically, either using a biopsy or surgical 
specimen. Staging procedure was done using the TNM 
system. Metastatic disease was evaluated clinically 
supported by imaging studies such as chest X-ray, 
abdominal ultrasound, abdominal or head computed 
tomography (CT) scanning, magnetic resonance 
imaging, and bone scan. Stage IV disease was de ned 
as the evidence of any distant malignant process at 
diagnosis. Relapse disease was de ned as the evidence 
of any distant recurrence with or without loco regional 
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recurrence after primary treatment has been completed 
without evidence of any clinical residual disease.
Patients’ demographics were presented descriptively. 
Overall survival was calculated from the date of diagnosis 
for stage IV group or the date of relapse diagnosis for 
relapsed group until the patient died or the last date 
of follow-up. Overall survival was analyzed using the 
Kaplan-Meier curve and log-rank test. A p value of less 
than 0.05 was considered signi cant. Data were analyzed 
using the statistical software SPSS for Windows version 
11.5 (SPSS Inc., Chicago, Illinois, USA).
RESULTS
There were 104 patients with colorectal cancer 
during the study period; 22 (21.2%) of them present 
with stage IV disease and 17 (16.3%) other were 
relapsed patients giving a total of 39 mCRC cases 
as the study subjects. Their mean age was 57.4 ± 
13.3 years, ranging from 30 to 84 years old. The 
peak age was between 51 and 60 years. Liver and 
lung were the predominant sites of metastasis, which 
were found in 28 (71.8%) and 17 (43.6%) patients, 
respectively. Twenty- ve (64.1%) patients presented 
with colon cancer (Table 1). Adenocarcinoma was 
Table 1. Characteristics of the study subjects (n = 39)
Variable n (%)
Sex
Male 21 (53.8)
Female 18 (46.2)
Age group (years)
21 – 30 1 (2.6)
31 – 40 3 (7.7)
41 – 50 8 (20.5)
51 – 60 12 (30.8) 
71 – 80 3 (7.7)
> 80 3 (7.7)
Location
Colon 25 (64.1)
Rectum or rectosigmoid 14 (35.9)
Site of metastasis
Liver only 14 (35.9)
Liver and lung 9 (23.1)
Lung only 4 (10.3)
Liver and bone 2 (5.1)
Ovary 1 (2.6)
Pancreas 1 (2.6)
Liver and ovary 1 (2.6)
Lung and bone 1 (2.6)
Lung and ovary 1 (2.6)
Bone and kidney 1 (2.6)
Intestinal wall 1 (2.6)
Liver, lung and brain 1 (2.6)
Liver, lung and kidney 1 (2.6)
Liver, kidney and bladder 1 (2.6)
Figure 1. Kaplan-Meier survival curve analyses of patients 
with colon or rectal cancer. The difference was not statitically 
signi cant (log-rank p = 0.147)
the only histopathology found in these cases. Three 
patients were excluded from the analysis due refusal 
to treatment, returning to home country (Japan), 
and having other primary cancer (malignant mixed 
Müllerian cancer of the ovary).
All patients received the combination of 
5- uorouracil (5-FU)/leucovorin (LV), oxaloplatin for 
4 cycles (FOLFOX4) as the standard  rst-line regimen 
for mCRC in Indonesia. Oral capecitabine and targeted 
therapy such as bevacizumab and cetuximab were 
also given, whenever indicated. Some patients may 
need additional treatment, such as palliative hepatic 
resection and radiotherapy for pain alleviation. 
Nineteen (48.7%) patients died during the study 
period, while the rest were alive or lost of follow-
up. The median overall survival of patients was 
18 months (95% CI = 6.98–29.02 months). The 
longest survival was 76 months (the patient is still 
alive when this manuscript was being prepared). 
Patients with colon cancer tended to live longer 
than rectal cancer, i.e. 21 vs. 15 months; log-rank 
p = 0.147 (Figure 1). There was no significant 
difference of survival between patients with stage IV 
disease and relapse cases, i.e. 18 vs. 12 months, log-
rank p = 0.807 (Figure 2). 
The median survival of patients who received 
FOLFOX (with or without oral capecitabine or 
targeted therapy) has not been reached at the time of 
the preparation of this article, while patients who did 
not receive FOLFOX regimen had a median survival of 
12 months. This difference was statistically signi cant 
(Figure 3). Furthermore, 5 of 15 (33%) patients who 
received FOLFOX had survival more than 2 years.
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intentionally selected from a private hospital because 
 nancially they can afford chemotherapy regimen. Our 
results con rmed the bene t of oxaliplatin. Median 
survival of 18 months were comparable with other 
studies. The survival bene t was seen either in stage IV 
patients or relpase cases. This observation emphasize 
the importance of adequate treatment of patients with 
metastatic disease, regardless prior stage. 
FOLFOX regimen given for four cycles continuously 
(FOLFOX4) has been routinely used as the  rst-line 
option for mCRC in Indonesia. However, OPTIMOX1 
trial suggested that physicians may opt to stop high-
dose oxaliplatin after 6 cycles, followed by infusional 
FU/LV and then reintroduce oxaliplatin again 
(“stop-and-go”).11 This approach was introduce after 
recognizing that the majority of patients treated with 
continues FOLFOX will discontinue for neurotoxicity 
before progression.
In further trials addressing complete discontinuation 
of treatment, the OPTIMOX2 trial failed to show clear 
bene t and suggested that chemotherapy should not 
be discontinued.12 To achieve prolonged survival, a 
complete stop of all therapy is not the correct strategy.13 
This applies not only to chemotherapy but other 
treatment modalities as well, as palliative surgery and 
radiotherapy Study showed that median survivas may 
exceed 30 months and more patients could live up 
to 4 and 5 years with advanced disease after hepatic 
resection and improved chemotherapy.14
Multiple cytotoxic agents and targeted therapy has 
been accepted as the standard treatment for mCRC. 
Instead of giving treatment sequentially as the disease 
progress, a more continuous approach has been 
suggested, whereby individualization of care is offered 
before it happens, the so-called ‘continuum of care’.15 
However, at the end of the day, the role of biologicals 
(popularly known as “targeted therapy”) have been 
modest at best, as they have not been shown to be active 
in the adjuvant setting – the most important phase of 
chemotherapy in colorectal cancer.17
There was a limitation in this study which warrants 
further improvement in documentation, as clinical factors 
were not included. A cohort prospective design would be 
a preferrable method for survival study; however, without 
a proper baseline data, such study would be dif cult to 
plan and too expensive, but this current study would serve 
as a platform for further clinical research on treatment of 
advanced colorectal in Indonesia.
To be fair, suf ce it to say that the conditions in 
Indonesia, though in varying degrees – is not unique. 
Improvement in survival has been aknowledged with the 
Figure 3. Kaplan-Meier survival curve analyses of patients who 
received FOLXOX chemotherapy or not. The difference was 
statitically signi cant (log-rank p = 0.01)
DISCUSSION
The ongoing research into the characteristic 
of cancer and recent advances in the treatment of 
metastatic colorectal cancer have resulted in change in 
outlook and the decision-making of the clinician to be 
ever more complex, such that the endeavour to prolong 
survival will have to take into consideration on quality 
of life. The advent of newer drugs, regimens, and the 
use of targeted therapies - mostly the monoclonal 
antibodies – mCRC has subsequently become a chronic 
disease with a median overall survival (mOS) of more 
than 2 years and a 5-year survival of 10% (previous 
 gures stated as 5%). 
This is the first clinical study in in Indonesia 
evaluating mCRC in hospital setting since the 
introduction of FOLFOX regimen. Cases were 
Figure 2. Kaplan-Meier survival curve analyses of patients with 
stage IV or relapsed diseases. The difference was not statitically 
signi cant (log-rank p = 0.807)
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use of more and better drugs. Yet we  nd that the bene ts 
of treatment have not been satisfactory as they have not 
touched the whole population, especially for the elderly.18
After the results of the N9741 Trial was announced,19 
in which 5-year survival of the FOLFOX regimen was 
shown to be higher than irinotecan plus  uorouracil 
and leucovorin (IFL), the overall survival (OS) 
and time to progression (TTP) 20.2 months and 8.9 
months, respectively, chemotherapy for colorectal 
cancer has not moved back ever since. Following in the 
footsteps and in mCRC, the use of “targeted therapy” 
or biologicals – as it is now more commonly known 
- a more personalized approach, started by the use of 
KRAS testing as a marker, has been regarded as the 
direction in the last decade.20 The bene ts of targeted 
therapy itself were earlier reported in 2009 by Chau 
with the use of bevacizumab,21 in which its use was 
reported to improve ef cacy (over the use of cytostatics 
alone) both as  rst and second-line treatment. But it 
was the KRAS test which forged the importance of 
markers. In our series, the use of KRAS has been 
minimal at best, mostly due to technical dif culties 
and cost. This has been the reason that bevacizumab 
was more utilized in our patients.
The road to the “perfect treatment”, for Indonesians 
and the rest of the world in that matter, is a long way off. 
Much has been accomplished, although the last decade 
did not meet expectations for the targeted therapies,22 and 
the answer may lie perhaps with cellular phenotyping,22 
correlated with chemotherapy regimens and response to 
therapy, which for all practicality is a distant horizon.
CONCLUSION
Patients with metastatic colorectal cancer have 
a modest survival with a median of 18 months. In 
our study, the chance to live longer was comparable 
between stage IV and relapsed patients. Chemotherapy 
combination with FOLFOX signi cantly prolongs 
survival, with about one-third of patients live longer 
than 2 years, a figure not unlike reported in the 
literature. We conclude that, with proper treatment 
and care, Indonesian colorectal cancer patients have 
the same survival as in developed countries. 
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